ライフサイエンスコーパス: systolic dysfunction

1 e is increasingly performed in patients with systolic dysfunction.

2 cardial disease with marked left ventricular systolic dysfunction.

3 monary hypertension (PH) in patients with LV systolic dysfunction.

4 hypertrophy, left chambers alterations, and systolic dysfunction.

5 results in extensive myocardial necrosis and systolic dysfunction.

6 r apical pacing may promote left ventricular systolic dysfunction.

7 r wall edema was not coupled with aggravated systolic dysfunction.

8 crease in contractility (-54%; P<0.001) with systolic dysfunction.

9 ated with revascularization in patients with systolic dysfunction.

10 dilation associated with mild nonprogressive systolic dysfunction.

11 diac [dATP] as a therapeutic option to treat systolic dysfunction.

12 t compared with subjects with more severe LV systolic dysfunction.

13 isk of SCD in patients with left ventricular systolic dysfunction.

14 RAs on SCD in patients with left ventricular systolic dysfunction.

15 k(+/+) marrow into Mertk(-/-) mice corrected systolic dysfunction.

16 e of death in patients with left ventricular systolic dysfunction.

17 nic heart failure caused by left ventricular systolic dysfunction.

18 k of death in patients with left ventricular systolic dysfunction.

19 ory patients with chronic heart failure with systolic dysfunction.

20 rmed safely in children with ESRD and severe systolic dysfunction.

21 strongest in patients with left ventricular systolic dysfunction.

22 especially in patients with left ventricular systolic dysfunction.

23 tion defects on the ECG and left ventricular systolic dysfunction.

24 th abnormal LV geometry but not diastolic or systolic dysfunction.

25 and specific biomarker for the detection of systolic dysfunction.

26 heart failure due to marked left ventricular systolic dysfunction.

27 ventricular dilation that is associated with systolic dysfunction.

28 th moderate to severe heart failure (HF) and systolic dysfunction.

29 al expression correlated with left ventricle systolic dysfunction.

30 and adverse LV remodeling associated with LV systolic dysfunction.

31 ng during infarct maturation associated with systolic dysfunction.

32 ents with heart failure and left ventricular systolic dysfunction.

33 coronary artery disease and left-ventricular systolic dysfunction.

34 entricular (LV) thrombus among patients with systolic dysfunction.

35 on, and presence/absence of left ventricular systolic dysfunction.

36 duced in LBBB patients with left ventricular systolic dysfunction.

37 nges in age, body mass index, creatinine, or systolic dysfunction.

38 lative and hypertrophic remodeling and worse systolic dysfunction.

39 ype 2 diabetes mellitus and left ventricular systolic dysfunction.

40 e, atrial fibrillation, and left ventricular systolic dysfunction.

41 asymptomatic patients with left ventricular systolic dysfunction.

42 ase AT susceptibility in HF patients with LV systolic dysfunction.

43 patients with asymptomatic left ventricular systolic dysfunction.

44 ogy and outcomes among patients with HF with systolic dysfunction.

45 asymptomatic patients with left ventricular systolic dysfunction.

46 der and etiology among patients with HF with systolic dysfunction.

47 congestion or edema, or (4) left ventricular systolic dysfunction.

48 gmental shortening and is a manifestation of systolic dysfunction.

49 ion in subjects with and without ventricular systolic dysfunction.

50 scents with symptomatic systemic ventricular systolic dysfunction.

51 s superior in some subgroups in detecting LV systolic dysfunction.

52 jury, hypertrophy, fibrosis, remodeling, and systolic dysfunction.

53 n models examined admission risk factors for systolic dysfunction.

54 tched diet induced obese mice do not display systolic dysfunction.

55 homeostasis in an efficient way to minimize systolic dysfunction.

56 rdiographic left ventricular hypertrophy and systolic dysfunction.

57 re, especially in patients with pre-existing systolic dysfunction.

58 tivessel disease and severe left ventricular systolic dysfunction.

59 in patients with CHF due to left ventricular systolic dysfunction.

60 ncrease in oxidative stress, hypertrophy and systolic dysfunction.

61 uction of mechanical stress in patients with systolic dysfunction.

62 directly associated with the development of systolic dysfunction.

63 patients with atrioventricular block and LV systolic dysfunction.

64 neutropenia or symptomatic left ventricular systolic dysfunction.

65 on in patients with heart failure because of systolic dysfunction.

66 patients with concomitant moderate AS and LV systolic dysfunction.

67 been predominantly confined to patients with systolic dysfunction.

68 e (ACE) inhibitors for left ventricular (LV) systolic dysfunction.

69 In subgroup analysis, patients with baseline systolic dysfunction (116 patients; mean EF, 44%) showed

70 years) complicated by left ventricular (LV) systolic dysfunction; (2) an age- and sex- matched hyper

71 aits: 1 each with LV internal dimensions and systolic dysfunction, 3 each with LV mass and wall thick

72 inhibitor/angiotensin receptor blockers for systolic dysfunction, (4) beta-blockers at discharge, (5

73 onsisted of left ventricular dilation (68%), systolic dysfunction (46%), and myocardial fibrosis (67%

74 on (21.3%), left atrial enlargement (15.3%), systolic dysfunction (6.3%), and ischemia (6.3%).

75 cant improvement in EF only in patients with systolic dysfunction (+7.44%; 95% CI, 5.4-9.5).

76 (LV) diastolic dysfunction, longitudinal LV systolic dysfunction, abnormal ventricular-arterial coup

77 dicted the development of end-stage HCM with systolic dysfunction (adjusted hazard ratio, 1.80/10% in

78 ents with heart failure and left ventricular systolic dysfunction after an acute myocardial infarctio

79 nto the cohort that developed left ventricle systolic dysfunction after catecholamine stress.

80 pendently associated with the development of systolic dysfunction after moderate-severe traumatic bra

81 Persistent severe left ventricular (LV) systolic dysfunction after myocardial infarction (MI) is

82 ric LV wall thickness, LV dilatation, and LV systolic dysfunction after TAC compared with control mic

83 re commonly associated with left ventricular systolic dysfunction, although isolated and early RV dys

84 vascular ischemia and prevention of overt LV systolic dysfunction, although randomized controlled tri

85 dividuals with asymptomatic left ventricular systolic dysfunction (ALVSD), especially in populations

86 pendently associated with the development of systolic dysfunction among moderate-severe traumatic bra

87 infusion, but that Micu2(-/-) mice exhibited systolic dysfunction and 30% lethality from abdominal ao

88 and prevent the development of tumor-induced systolic dysfunction and atrophy.

89 tality in medically treated patients with LV systolic dysfunction and CAD, nor does it identify patie

90 her CABG improved angina in patients with LV systolic dysfunction and CAD.

91 ) (P < .001); prevalence of left ventricular systolic dysfunction and chronic kidney disease also inc

92 trial and ventricular remodeling, along with systolic dysfunction and comparable intra-cardiac fibros

93 med any single cytokine in the prediction of systolic dysfunction and death.

94 ypertrophy with concentric geometry precedes systolic dysfunction and heart failure.

95 rtrophic response is a major risk factor for systolic dysfunction and heart failure.

96 ) is a common form of cardiomyopathy causing systolic dysfunction and heart failure.

97 In post-myocardial infarction with systolic dysfunction and HF, low serum chloride was asso

98 ion fraction less than 20%; left ventricular systolic dysfunction and history of previous stroke; and

99 diovascular disease and indexes of global LV systolic dysfunction and hypertrophy (HR: 1.80; 95% CI:

100 ng-term LVEF, reduced incidence of severe LV systolic dysfunction and ICD indications, and fewer hear

101 These changes lead to diastolic and systolic dysfunction and impaired reserve capacity.

102 to an angiotensin II/AT1 receptor-dependent systolic dysfunction and impaired vascular function.

103 or of events independent of left ventricular systolic dysfunction and ischemia (relative risk = 1.84,

104 dard risk factors including left ventricular systolic dysfunction and ischemia.

105 he prevalence of overt left ventricular (LV) systolic dysfunction and its associated risk factors hav

106 ynchrony indexes in patients with or without systolic dysfunction and left bundle-branch block.

107 e specific for dyssynchrony in patients with systolic dysfunction and left bundle-branch block.

108 survival were severity of right ventricular systolic dysfunction and low diastolic blood pressure.

109 Left ventricular (LV) systolic dysfunction and moderate aortic stenosis (AS) a

110 ents with heart failure and left ventricular systolic dysfunction and patients with heart failure and

111 al mechanisms pertaining to left ventricular systolic dysfunction and remodeling, systemic inflammati

112 and the greatest degree of left ventricular systolic dysfunction and remodeling.

113 ed with adverse left ventricular remodeling, systolic dysfunction, and a reduction in survival in the

114 ilation, increased cardiomyocyte cell death, systolic dysfunction, and conduction abnormalities.

115 nificant coronary stenoses, left ventricular systolic dysfunction, and death during follow-up.

116 chronic heart failure, left ventricular (LV) systolic dysfunction, and hospitalisation for heart fail

117 h systolic HF, CSA, severe right ventricular systolic dysfunction, and low diastolic blood pressure m

118 tion, including arrhythmia, left ventricular systolic dysfunction, and myocardial infarction.

119 pulations, in patients with left ventricular systolic dysfunction, and particularly when substantial

120 nostic impact over and above LV dilation, LV systolic dysfunction, and presence of LGE.

121 D exhibit features of early LV diastolic and systolic dysfunction, and these abnormalities are more s

122 t, markers of LV relaxation, longitudinal LV systolic dysfunction, and ventricular-arterial coupling

123 Patients with concomitant moderate AS and LV systolic dysfunction are at high risk for clinical event

124 diomyopathy, manifested by LV dilatation and systolic dysfunction, as well as overexpression of genes

125 ts experienced significant right ventricular systolic dysfunction at discharge and 1 month with norma

126 0(+) STEMI patients had an increased risk of systolic dysfunction at discharge and an increased risk

127 ith dilated cardiomyopathy without severe LV systolic dysfunction at high risk of SCD.

128 l fibrosis, and to some extent to myocardial systolic dysfunction attributable to the shift of calciu

129 present with heart failure, left ventricular systolic dysfunction, AV block, atrial or ventricular ar

130 reduce SR Ca available for release, causing systolic dysfunction; (b) elevate diastolic [Ca]i, contr

131 cal data of patients with moderate AS and LV systolic dysfunction between 2010 and 2015 from 4 large

132 For patients with atrioventricular block and systolic dysfunction, biventricular pacing not only redu

133 vival rates and symptoms in patients with LV systolic dysfunction but little is known about its effec

134 coronary artery disease and left-ventricular systolic dysfunction, but could be used to reduce the in

135 ction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % eject

136 e investigated whether left ventricular (LV) systolic dysfunction by global longitudinal strain (GLS)

137 LV systolic dysfunction by GLS was a powerful and independe

138 ical Rate Control in Atrial Fibrillation and Systolic Dysfunction [CAMERA-MRI]; ACTRN12613000880741).

139 Early systolic dysfunction can occur in previously healthy pat

140 rt damage, characterized by left-ventricular systolic dysfunction, cardiac hypertrophy and myocardial

141 ar regurgitation, and less right ventricular systolic dysfunction compared with SAVR.

142 Patients with left ventricular (LV) systolic dysfunction, coronary artery disease (CAD), and

143 an increased prevalence of left ventricular systolic dysfunction cross-sectionally and an elevated r

144 ype, family history of CM (DCM), severity of systolic dysfunction (DCM), and extent of LV hypertrophy

145 valve area between 1.0 and 1.5 cm(2) and LV systolic dysfunction defined as LV ejection fraction <50

146 In these patients, LV systolic dysfunction, defined in the guidelines as eject

147 This dynamic systolic dysfunction, demonstrated on the Doppler curves

148 Left ventricular systolic dysfunction determined by reduced strain-rate s

149 diography in patients with various levels of systolic dysfunction, diastolic abnormalities, and valvu

150 rative care reduced the combined rates of LV systolic dysfunction, diastolic dysfunction, and heart f

151 xhibited basal echocardiographic findings of systolic dysfunction, diastolic dysfunction, and hypertr

152 dial ischemia, left ventricular hypertrophy, systolic dysfunction, diastolic dysfunction, or left atr

153 The degree of left ventricular (LV) systolic dysfunction did not correlate with the quantity

154 or identification of patients with severe LV systolic dysfunction (EF <or= 35%), PEC time was highly

155 , focusing on patients with left ventricular systolic dysfunction, either nonischemic or ischemic.

156 tivessel disease and severe left ventricular systolic dysfunction (ejection fraction </=35%) who unde

157 ociated with overt left or right ventricular systolic dysfunction (ejection fraction <50%).

158 Graft dysfunction was defined as significant systolic dysfunction (ejection fraction [EF] <45%) or th

159 c cardiomyopathy and severe left ventricular systolic dysfunction (ejection fraction</=35%).

160 coronary artery disease and left-ventricular systolic dysfunction, elevated heart rate (70 bpm or gre

161 ass II to IV heart failure and predominantly systolic dysfunction enrolled in 6 randomized trials or

162 (-/-) mice developed cardiac hypertrophy and systolic dysfunction, evidenced by a 5-fold greater hear

163 tric hypertrophy preceded the development of systolic dysfunction, fetal gene activation, fibrosis, a

164 In patients with severe systolic dysfunction following acute MI with an EF </=35

165 important, particularly among patients with systolic dysfunction, for whom most HF-specific therapie

166 Patients with systolic dysfunction frequently demonstrate multiple pat

167 dy demonstrates that in rats with MI induced systolic dysfunction, GGF2 treatment improves cardiac fu

168 strictive diastolic stage, right ventricular systolic dysfunction > or =3+, and tricuspid regurgitati

169 echocardiography documented left ventricular systolic dysfunction had a central venous oxygen saturat

170 Patients with LV systolic dysfunction had a significantly lower UR (-55 o

171 ator of HFpEF, the prevalence of concomitant systolic dysfunction has not been clearly defined.

172 cal coupling, a well-described phenomenon in systolic dysfunction, has not been well studied in diast

173 HF risk factors, antecedent left ventricular systolic dysfunction (hazard ratio, 2.33; 95% confidence

174 l infarction complicated by left ventricular systolic dysfunction; however, the perceived risk of hyp

175 I]: 1.20 to 1.83) and right ventricular (RV) systolic dysfunction (HR: 1.68; CI: 1.35 to 2.07).

176 Systolic dysfunction in Akita/ACE2KO mice was linked to

177 Smaller Ca2+ transients and systolic dysfunction in heart failure (HF) can be largel

178 dysfunction in wild-type mice, and profound systolic dysfunction in mice lacking cardiac PGC-1alpha.

179 g (EAM) in identifying irreversibility of LV systolic dysfunction in patients with left ventricular n

180 dinal course, and admission risk factors for systolic dysfunction in patients with moderate-severe tr

181 tcomes of asymptomatic left ventricular (LV) systolic dysfunction in patients with severe aortic sten

182 to uncover unsuspected left ventricular (LV) systolic dysfunction in patients with stable COPD.

183 The presence of severe systolic dysfunction in pediatric dialysis patients shou

184 s, p47(phox)KO mice showed markedly worsened systolic dysfunction in response to pressure overload at

185 eveloping cardiac hypertrophy, fibrosis, and systolic dysfunction in response to transverse aortic co

186 ntricular [LV] outflow obstruction or due to systolic dysfunction in the absence of obstruction; or a

187 ility in patients with left ventricular (LV) systolic dysfunction in whom worsening heart failure (HF

188 In this large cohort of patients with LV systolic dysfunction, in whom FMR and LV characteristics

189 ebo group had cardiac hypertrophy, fibrosis, systolic dysfunction, increased oxidized to total glutat

190 as common in our HD study population, and RV systolic dysfunction independently predicted mortality.

191 severe AS, the prevalence of asymptomatic LV systolic dysfunction is 0.4%.

192 Systolic dysfunction is associated with increased risk f

193 safety among patients with left ventricular systolic dysfunction is based on small populations, and

194 an twice as high as in control subjects, and systolic dysfunction is equally reduced in SCM and LAD M

195 phy and diastolic dysfunction; a subclinical systolic dysfunction is evident only in PA.

196 In chronic Chagas disease, RV systolic dysfunction is more commonly associated with le

197 is preserved in RA patients, indicating that systolic dysfunction is not an intrinsic feature of RA.

198 In conclusion, systolic dysfunction is strongly associated with mortali

199 the impact of lesser degrees of ventricular systolic dysfunction is unknown.

200 a decrease in diastolic function followed by systolic dysfunction later in life.

201 l infarction complicated by left ventricular systolic dysfunction (left ventricular ejection fraction

202 determined in 784 consecutive patients with systolic dysfunction (left ventricular ejection fraction

203 rved in the term-born adults and 6% had mild systolic dysfunction (<45%).

204 e of AVB, AA, sustained VA, left ventricular systolic dysfunction (LVD) (= left ventricular ejection

205 een (18%) patients had left ventricular (LV) systolic dysfunction (LVEF </=45%).

206 ker (ARB) for patients with left ventricular systolic dysfunction (LVEF <0.40) and prescription of wa

207 Patients with systolic dysfunction (LVEF <or= 0.40) had significantly

208 Among patients with left ventricular systolic dysfunction (LVSD) (n = 3,001), beta-blockers w

209 Left ventricular systolic dysfunction (LVSD) accounts for almost 25% of n

210 mpared 20,118 patients with left ventricular systolic dysfunction (LVSD) and 21,149 patients with PSF

211 k factor for development of left ventricular systolic dysfunction (LVSD) and can complicate LVSD mana

212 not differentiated between left ventricular systolic dysfunction (LVSD) and HF with preserved ejecti

213 raphy examination to define left ventricular systolic dysfunction (LVSD) and left ventricular diastol

214 ata, including grade 3 to 4 left ventricular systolic dysfunction (LVSD) and significant asymptomatic

215 t failure (HF) secondary to left ventricular systolic dysfunction (LVSD) are frequently deficient in

216 trial fibrillation (AF) and left ventricular systolic dysfunction (LVSD) frequently co-exist despite

217 Some patients with left ventricular systolic dysfunction (LVSD) have a dramatic improvement

218 ciated with the severity of left ventricular systolic dysfunction (LVSD) in patients with chronic Cha

219 revent chemotherapy-induced left ventricular systolic dysfunction (LVSD) in patients with hematologic

220 d by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reductio

221 entricular failure (RVF) in left ventricular systolic dysfunction (LVSD) is associated with high morb

222 p analyses of patients with left ventricular systolic dysfunction (LVSD) suggest marginal benefit of

223 examined the prevalence of left ventricular systolic dysfunction (LVSD), diastolic dysfunction (DD),

224 determine the prevalence of left ventricular systolic dysfunction (LVSD), including symptomatic (ie,

225 In patients with left ventricular systolic dysfunction (LVSD), the rate at which oxygen up

226 e men, and 1791 (40.2%) had left ventricular systolic dysfunction (LVSD).

227 ents with AMI without HF or left ventricular systolic dysfunction (LVSD).

228 he study patients developed left ventricular systolic dysfunction (mean [SD] ejection fraction, 25% [

229 y ECG or echocardiography], left ventricular systolic dysfunction, microalbuminuria, and a reduced an

230 enrolling 2,331 ambulatory HF patients with systolic dysfunction (New York Heart Association functio

231 AT1 receptor blocker, irbesartan rescued the systolic dysfunction, normalized altered signaling pathw

232 In patients with HF due to LV systolic dysfunction, NT-proBNP-guided therapy was super

233 D often deprives patients with CHF due to LV systolic dysfunction of the most beneficial pharmacologi

234 d tissue angiotensin II levels, resulting in systolic dysfunction on a background of impaired diastol

235 had diastolic dysfunction in the absence of systolic dysfunction or cardiac hypertrophy.

236 y and not a surrogate for the severity of LV systolic dysfunction or FMR.

237 vs. 5%; p = 0.013); 3) higher prevalence of systolic dysfunction or restrictive LV filling at last e

238 the absence of significant left ventricular systolic dysfunction or valve disease, due to impaired v

239 ilure usually does not result from transient systolic dysfunction or valvular abnormalities but rathe

240 kely to have heart failure, left ventricular systolic dysfunction, or atrial tachyarrhythmia.

241 To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization

242 reach class I indications of symptoms or LV systolic dysfunction, particularly in patients with dege

243 tivessel disease and severe left ventricular systolic dysfunction, PCI with everolimus-eluting stent

244 onduction abnormalities and left ventricular systolic dysfunction predisposing to heart failure.

245 e expansion (VE) in humans with pre-clinical systolic dysfunction (PSD) and pre-clinical diastolic dy

246 igher death risk included LVEF </=45% and RV systolic dysfunction rather than neither (HR: 2.04; CI:

247 th stable heart failure and left ventricular systolic dysfunction receiving guideline-indicated treat

248 ctional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy.

249 All patients with early systolic dysfunction recovered in 1 week.

250 , heart failure, and severe left ventricular systolic dysfunction remains unclear.

251 nical significance of right ventricular (RV) systolic dysfunction (RVD) in patients with heart failur

252 ostic significance of right ventricular (RV) systolic dysfunction (RVSD).

253 ion in transgenic mice with left ventricular systolic dysfunction secondary to overexpression of tumo

254 ventricular diastolic and right ventricular systolic dysfunction seem to explain the association of

255 Patients with systolic dysfunction show ventricular AP amplitude alter

256 patients with asymptomatic left ventricular systolic dysfunction (Stage B HF) and how to prevent its

257 cancer cachexia-induced cardiac atrophy and systolic dysfunction, suggesting therapies that may help

258 lization in this well-treated HF cohort with systolic dysfunction, supporting recommendations that ti

259 in patients in sinus rhythm with significant systolic dysfunction, symptomatic heart failure, and pro

260 Hypertension, obesity, and systolic dysfunction that are present before a person is

261 the rates of hypertension, left ventricular systolic dysfunction, the hand-foot syndrome, and mucosi

262 groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia a

263 14 patients (38%) presented left ventricular systolic dysfunction; there were significant association

264 In a broad cross section of patients with systolic dysfunction, thrombus prevalence was 7% by DE-C

265 me of AFCA in patients with left ventricular systolic dysfunction, to evaluate predictors of recurren

266 ies including patients with left ventricular systolic dysfunction undergoing AFCA were included.

267 mmunity-based patients with left ventricular systolic dysfunction undergoing primary prevention ICD i

268 trate in patients with left ventricular (LV) systolic dysfunction undergoing prophylactic implantable

269 Six children with ESRD and severe systolic dysfunction underwent renal transplantation.

270 Five hundred eight patients with CHF due to systolic dysfunction underwent resting cardiovascular me

271 eased vasopressor support (right ventricular systolic dysfunction, unremarkable transesophageal echoc

272 of future arrhythmic events in patients with systolic dysfunction using the gold standard of cardiova

273 in patients with chronic heart failure with systolic dysfunction, using patient data that are routin

274 By multivariate analysis, LV systolic dysfunction was associated with a 5-fold increa

275 sion analyses confirmed that circumferential systolic dysfunction was associated with log transformed

276 ssessed by transthoracic echocardiogram, and systolic dysfunction was defined as fractional shortenin

277 RV systolic dysfunction was defined as reduced RV ejection

278 Subclinical left ventricular (LV) systolic dysfunction was defined using values of absolut

279 t ventricular ejection fraction, isolated RV systolic dysfunction was found in 7 (4.4%) patients, 2 o

280 osis was present in 55 patients (72%) and LV systolic dysfunction was identified in 13 patients (24%)

281 RV systolic dysfunction was identified in 58 (37%) individu

282 At diagnosis, LV systolic dysfunction was present in 20% of subjects and

283 Left ventricular systolic dysfunction was significantly impaired after ca

284 Heart failure because of systolic dysfunction was the most common clinical presen

285 Patients with LV systolic dysfunction were at considerably higher risk fo

286 art failure attributable to left ventricular systolic dysfunction were examined in this post hoc anal

287 Multivariate modeling showed that those with systolic dysfunction were nearly twice as likely to die

288 mptomatic heart failure and left ventricular systolic dysfunction were randomized to either 24 weeks

289 ubjects with HF due to left ventricular (LV) systolic dysfunction were randomized to receive either s

290 specific (86.1%) biomarker for detecting LV systolic dysfunction, which was comparable to BNP(1-32),

291 concentric LV remodeling with diastolic and systolic dysfunction, which was prevented by both HIT an

292 nd cisplatin), and one from left ventricular systolic dysfunction, which was probably related to MAPI

293 ents with heart failure and left ventricular systolic dysfunction who are treated with standard thera

294 etic registries with HF and left ventricular systolic dysfunction who were discharged on beta-blocker

295 study was conducted in patients with HF and systolic dysfunction who were receiving standard therapy

296 on was used to verify the relationship of RV systolic dysfunction with age, sex, functional class, us

297 with dengue in the form of left ventricular systolic dysfunction with increased left myocardial perf

298 atrioventricular block and left ventricular systolic dysfunction with NYHA class I, II, or III heart

299 R46 SNP was significantly associated with LV systolic dysfunction, with each minor allele additively

300 0%) mild traumatic brain injury patients had systolic dysfunction within the first day after injury (